Targeting matrix remodeling in cardiac hypertrophy and heart failure

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 3, 2005, Pages 253-258

  Lindsey, Merry L ^a   Spinale, Francis G ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; BOSENTAN; CARDIOVASCULAR AGENT; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; IRBESARTAN; MATRIX METALLOPROTEINASE; NEBIVOLOL; OSTEONECTIN; OSTEOPONTIN; OSTEOPONTIN BLOCKING AGENT; PERINDOPRIL; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SMAD PROTEIN; SPIRONOLACTONE; TENASCIN; THROMBOSPONDIN; THROMBOSPONDIN BLOCKING AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART STRESS; HEART VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 27144441381     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.08.001     Document Type: Review

References (32)

1. M.R. Zile and D.L. Brutsaert New concepts in diastolic dysfunction and diastolic heart failure: Part I: Diagnosis, prognosis, and measurements of diastolic function Circulation 105 2002 1387-1393
2. W. Grossman Defining diastolic dysfunction Circulation 101 2000 2020-2021
3. F. Kuwahara et al. Hypertensive myocardial fibrosis and diastolic dysfunction: Another model of inflammation? Hypertension 43 2004 739-745
4. A.V. Chobanian et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report JAMA 289 2003 2560-2571
5. C. Gutierrez and D.G. Blanchard Diastolic heart failure: Challenges of diagnosis and treatment Am. Fam. Physician 69 2004 2609-2616
6. P.M. Mottram et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure Circulation 110 2004 558-565
7. K. Yamamoto et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart Cardiovasc. Res. 55 2002 76-82
8. C. Brilla et al. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension Herz 28 2003 744-753
9. R.D. Brown et al. The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure Annu. Rev. Pharmacol. Toxicol. 45 2005 657-687
10. F. Zannad et al. Limitation of excessive extracellular matrix turnover contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). RALES Investigators Circulation 102 2000 2700-2706
11. M.M. Chen et al. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: A potential role in heart fibrosis J. Mol. Cell. Cardiol. 32 2000 1805-1819
12. M.S. Ahmed et al. Connective tissue growth factor - a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats J. Mol. Cell. Cardiol. 36 2004 393-404
13. H. Chen et al. Gene expression changes associated with fibronectin-induced cardiac myocyte hypertrophy Physiol. Genomics 18 2004 273-283
14. M.S. Ahmed et al. Induction of myocardial connective tissue growth factor in pacing-induced heart failure in pigs Acta Physiol. Scand. 184 2005 27-36
15. Z. He et al. Differential regulation of angiotensin II-induced expression of connective tissue growth factor by protein kinase C isoforms in the myocardium J. Biol. Chem. 280 2005 15719-15726
16. F. Kuwahara et al. Transforming growth factor-{beta} function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats Circulation 106 2002 130-135
17. W.S. Bradham et al. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: A current perspective Cardiovasc. Res. 53 2002 822-830
18. M. Komajda et al. The role of the neurohormonal system in heart failure Heart 79 1998 17S-23S
19. A. Ray et al. Endothelin-receptor antagonists: Current and future perspectives Drug Discov. Today 5 2000 455-464
20. M.W.M. Schellings et al. Matricellular proteins in the heart: Possible role during stress and remodeling Cardiovasc. Res. 64 2004 24-31
21. F.G. Spinale Cell-matrix signaling and thrombospondin: Another link to myocardial matrix remodeling Circ. Res. 95 2004 446-448
22. B. Schroen et al. Thrombospondin-2 is essential for myocardial matrix integrity: Increased expression identifies failure-prone cardiac hypertrophy Circ. Res. 95 2004 515-522
23. J.F. Woessner Jr. MMPs and TIMPs - an historical perspective Mol. Biotechnol. 22 2002 33-49
24. Y.Y. Li et al. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure Am. J. Physiol. Heart Circ. Physiol. 282 2002 H983-H989
25. M.M. Lindsay et al. TIMP-1: A marker of left ventricular diastolic dysfunction and fibrosis in hypertension Hypertension 40 2002 136-141
26. M.H. Tayebjee et al. Tissue inhibitor of metalloproteinse-1 is a marker of diastolic dysfunction using tissue Doppler in patients with type 2 diabetes and hypertension Eur. J. Clin. Invest. 35 2005 8-12
27. W.C. Little et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure J. Card. Fail. 11 2005 191-195
28. J. Liu et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart Am. J. Physiol. Heart Circ. Physiol. 285 2003 H2587-H2591
29. V. Thallas-Bonke et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-{alpha}-dependent pathway Diabetes 53 2004 2921-2930
30. S. Vasan et al. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks Arch. Biochem. Biophys. 419 2003 89-96
31. D.A. Kass et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker Circulation 104 2001 1464-1470
32. F. Cipollone et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control Circulation 108 2003 1070-1077